OBJECTIVES: The newborn screening (NBS) program in the Republic of Serbia has several decades of tradition, but it has not included any organic acidemias (OA). Therefore, this study aimed to establish the cut-offs of the corresponding NBS markers in the population of healthy newborns. METHODS: In dried blood samples (DBS) collected from 1,771 healthy newborns, we analyzed levels of propionylcarnitine (C3), isovalerylcarnitine (C5), and glutarylcarnitine (C5DC) using tandem mass spectrometry. Further we calculated the following ratios: C3/acetylcarnitine (C3/C2), C3/palmitoylcarnitine (C3/C16), C5/ free carnitine (C0), C5/C2, C5/C3, C5DC/octanoylcarnitine (C8), and C5DC/C0. RESULTS: The cut-offs for methylmalonic acidemia (MMA) or propionic acidemia (PA) were C3>5.73 μmol/L, C3/C2>0.23, and C3/C16>2.36. Based on the study findings, the screening results indicative for isovaleric acidemia (IVA) would include C5>0.372 μmol/L, C5/C0>0.020, C5/C2>0.019, and C5/C3>0.31. Finally, C5DC>0.303 μmol/L, C5DC/C8>7.1, and C5DC/C0>0.019 would justify further testing for glutaric acidemia type I (GA1). The cut-offs were satisfactorily validated via the comparison with worldwide estimates and data for several Caucasian populations. CONCLUSIONS: The levels of the OA biomarkers in the Serbian population of healthy newborns have a distribution pattern similar to the other world populations. Therefore, the proposed cut-offs represent a reliable starting point for the future development of the OA NBS.

Center for Medical Biochemistry University Clinical Center of Serbia Belgrade Serbia

Clinic for Gynecology and Obstetrics University Clinical Centre of Serbia Belgrade Serbia

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Faculty of Medical Sciences University of Kragujevac Kragujevac Serbia

School of Medicine University of Belgrade Belgrade Serbia

See more in PubMed

Wajner, M. Neurological manifestations of organic acidurias. Nat Rev Neurol 2019;15:253–71. https://doi.org/10.1038/s41582-019-0161-9.

Villani, GRD, Gallo, G, Scolamiero, E, Salvatore, F, Ruoppolo, M. “Classical organic acidurias”: diagnosis and pathogenesis. Clin Exp Med 2017;17:305–23. https://doi.org/10.1007/s10238-016-0435-0.

Newborn Screening by Tandem Mass Spectrometry. CLSI guideline: NBS 04, 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

Hörster, F, Kölker, S, Loeber, JG, Cornel, MC, Hoffmann, GF, Burgard, P. Newborn screening programmes in Europe, arguments and efforts regarding harmonisation: focus on organic acidurias. JIMD Rep 2017;32:105–15.

Groselj, U, Zerjav Tansek, M, Smon, A, Angelkova, N, Anton, D, Baric, I, et al.. Newborn screening in southeastern Europe. Mol Genet Metabol 2014;113:42–5. https://doi.org/10.1016/j.ymgme.2014.07.020.

Stojiljkovic, M, Klaassen, K, Djordjevic, M, Sarajlija, A, Brasil, S, Kecman, B, et al.. Molecular and phenotypic characteristics of seven novel mutations causing branched-chain organic acidurias. Clin Genet 2016;90:252–7. https://doi.org/10.1111/cge.12751.

Beletić, A, Tijanić, A, Nikolić, T, Chrastina, P, Stefanović, A, Stanković, S. Acylcarnitines’ profile in the dried blood spot samples of healthy newborns from the Republic of Serbia-the pilot study. Serbian J Exp Clin Res, in press. https://doi.org/10.2478/sjecr-2021-0021.

McHugh, DMS, Cameron, CA, Abdenur, JE, Abdulrahman, M, Adair, O, Nuaimi, SAA, et al.. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 2011;13:230–54. https://doi.org/10.1097/GIM.0b013e31820d5e67.

Demirelce, Ö, Aksungar, FB, Saral, NY, Kilercik, M, Serteser, M, Unsal, I. Institutional experience of newborn screening for inborn metabolism disorders by tandem MS in the Turkish population. J Pediatr Endocrinol Metab 2020;33:703–11. https://doi.org/10.1515/jpem-2019-0571.

Guiñón, L, Solera, A, Molina, A, Marín, JL, López, RM, García-Villoria, J, et al.. Analytical performance specifications based on the state-of-the-art for the newborn screening. Clin Chim Acta 2020;510:117–20. https://doi.org/10.1016/j.cca.2020.07.006.

David, J, Chrastina, P, Pešková, K, Kožich, V, Friedecký, D, Adam, T, et al.. Epidemiology of rare diseases detected by newborn screening in the Czech Republic. Cent Eur J Publ Health 2019;27:153–9. https://doi.org/10.21101/cejph.a5441.

La Marca, G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal 2014;101:174–82. https://doi.org/10.1016/j.jpba.2014.03.047.

Vilarinho, L, Rocha, H, Sousa, C, Marcão, A, Fonseca, H, Bogas, M, et al.. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 2010;33:S133–8. https://doi.org/10.1007/s10545-010-9048-z.